ServiceUpdated on 10 September 2025
Platform for de novo Peptide Discovery
About
Biosynth developed a high-throughput screening platform for the de novo discovery of peptidic binders to any protein target of interest. The platform includes monocyclic peptides, Bibridged peptides, tricyclic peptides, as well as a newly developed model for biopanning using live cells (e.g. for membrane-embedded target proteins) and finally a high-throughput screening facility for affinity optimization of existing lead peptides.
Type
- Development
Applies to
- Innovative therapies - Precision medicine
- Development stages and support fuctions - Pre-clinical research and development
- Development stages and support fuctions - Contract research (CRO / CRMO)
Organisation
Similar opportunities
Service
CLIPS-tricycle mRNA library-screening platform
- Development
- Manufacturing
- Innovative therapies - Precision medicine
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Development stages and support fuctions - Pre-clinical research and development
Peter Timmerman
Head of Peptide Science at Biosynth B.V.
Lelystad, Netherlands
Service
- Development
- Manufacturing
- Innovative therapies - Precision medicine
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Development stages and support fuctions - Pre-clinical research and development
Peter Timmerman
Head of Peptide Science at Biosynth B.V.
Lelystad, Netherlands
Service
Life Science Products Covering the Entire Landscape
- Innovative therapies - Precision medicine
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Development and (GMP) manufacturing
- Development stages and support fuctions - Technology development and validation
Peter Timmerman
Head of Peptide Science at Biosynth B.V.
Lelystad, Netherlands